KYBORA, a leading global advisory firm specializing in biopharma transactions, is proud to announce its role as exclusive advisor to Bioprofarma Bagó in a significant in-licensing agreement with Polaris.
Under this strategic agreement, Bioprofarma Bagó (a fully owned subsidiary of Grupo Bagó), secured an exclusive licensing agreement with Polaris, to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer with limited treatment options, across the Latin American (LATAM) region.
This collaboration marks a critical step forward in expanding access to cutting-edge oncology treatments across Latin America. Under the terms of this agreement, Polaris will retain responsibility for the development and manufacturing of ADI-PEG20, while Bioprofarma Bagó will lead regulatory registration, obtain marketing authorization, and oversee importation and commercialization across LATAM markets.
This partnership will advance the treatment of Malignant Pleural Mesothelioma by introducing innovative therapeutic solutions designed to improve patient outcomes throughout the region. It also enables Bioprofarma Bagó to strategically expand into a high-need therapeutic area with limited treatment options, while also reinforcing its reputation among companies looking for partners with the capability to manage and sustain high-level collaborations.
“This alliance with Polaris marks an important milestone for us as a company responsible for delivering innovative products to patients and physicians”, stated Leonardo Fernández, General Manager of Bioprofarma Bagó.
“We are grateful for the strategic guidance of KYBORA, which also served as an effective accelerator, instrumental in achieving this transformative agreement and furthering our mission of making innovative therapies available in LatAm markets”.
KYBORA played a pivotal role in the structuring, negotiation, and facilitating the transaction.
With its broad international network and specialization in cross-border transactions, KYBORA ensured alignment between both companies’ goals and facilitated a deal that advances healthcare access across underserved regions.
“This partnership between Laboratorios Bagó and Polaris Pharmaceuticals is a powerful example of how strategic cross-border collaboration can unlock new opportunities for patients worldwide. We are proud to have supported this important transaction and to have helped bridge geographies and expertise across different regions”, said Vijay Murugan, Partner and Managing Director of KYBORA.
“This partnership reflects KYBORA’s leadership in executing cross-border transactions and our unwavering commitment to helping clients expand their global footprint while advancing impactful therapeutic solutions for patients.”
For more information, please click here.
About KYBORA
KYBORA is a global advisory firm and investment bank whose mission is to guide transformative healthcare companies to enduring success globally. We provide M&A, licensing, fundraising, and strategic advisory services to the global biopharma industry, creating value for our clients worldwide. With offices in the US, Switzerland, and China, and a direct presence in all key biopharma markets around the world, KYBORA offers unparalleled global reach and local knowledge. Contact us to explore how we can help you address your most pressing challenges.
